Dr. Skikne is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3901 Rainbow Blvd
Kansas City, KS 66160Phone+1 913-588-6000
Education & Training
University of Kansas School of MedicineFellowship, Hematology and Medical Oncology, 1977 - 1979
University of the WitwatersrandClass of 1969
Certifications & Licensure
KS State Medical License 1978 - 2025
Awards, Honors, & Recognition
- Top MD Consumers Checkbook
Clinical Trials
- Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia Start of enrollment: 2007 Sep 11
- Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple Myeloma Start of enrollment: 2008 Aug 12
- Study to Evaluate Pharmacokinetics, Food Effect, Safety and Efficacy of Oral Azacitidine Start of enrollment: 2012 Feb 07
- Join now to see all
Publications & Presentations
PubMed
- 224 citationsOral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission.Andrew H. Wei, Hartmut Döhner, Christopher Pocock, Pau Montesinos, Boris V. Afanasyev
The New England Journal of Medicine. 2020-12-24 - 92 citationsCytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care.Hartmut Döhner, Anna Dolnik, Lin Tang, John F. Seymour, Mark D. Minden
Leukemia. 2018-10-01 - 10 citationsPrognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine.Hartmut Döhner, Andrew H Wei, Gail J Roboz, Pau Montesinos, Felicitas R Thol
Blood. 2022-10-13
Abstracts/Posters
- Preliminary Results from a Phase II Study of the Combination of Pevonedistat and Azacitidine in the Treatment of MDS and MDS/MPN after Failure of DNA Methyltransferase...Barry S. Skikne, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- LAG3 Inhibition Decreases AML-Induced Immunosuppression and Improves T Cell-Mediated KillingBarry S. Skikne, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Press Mentions
Remembering James Cook, Oncology Researchers Receive 2020 NIH Director’s New Innovator Awards, and MoreFebruary 1st, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
